Phase II study of three dose levels of continuous erythropoietin receptor activator (C.E.R.A.) in anaemic patients with aggressive non-Hodgkin's lymphoma receiving combination chemotherapy

Anders Österborg, Juan Luis Steegmann, Andrzej Hellmann, Stephen Couban, Jiri Mayer, Joseph E. Eid

Research output: Contribution to journalArticlepeer-review

15 Citations (Scopus)
Original languageEnglish
Pages (from-to)736-744
Number of pages9
JournalBritish Journal of Haematology
Volume136
Issue number5
DOIs
Publication statusPublished - Mar 2007

ASJC Scopus Subject Areas

  • Hematology

Keywords

  • Anaemia
  • Chemotherapy
  • Continuous erythropoietin receptor activator (C.E.R.A.)
  • Non-Hodgkin's lymphoma
  • Phase II trial

Fingerprint

Dive into the research topics of 'Phase II study of three dose levels of continuous erythropoietin receptor activator (C.E.R.A.) in anaemic patients with aggressive non-Hodgkin's lymphoma receiving combination chemotherapy'. Together they form a unique fingerprint.

Cite this